Analysis of Predictors of Resection and Survival in Locally Advanced Stage III Pancreatic Cancer: Does the Nature of Chemotherapy Regimen Influence Outcomes?
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Analysis of Predictors of Resection and Survival in Locally Advanced Stage III Pancreatic Cancer: Does the Nature of Chemotherapy Regimen Influence Outcomes?
Authors
Keywords
Overall Survival, Gemcitabine, Stereotactic Body Radiotherapy, Chemotherapy Group, Vascular Resection
Journal
ANNALS OF SURGICAL ONCOLOGY
Volume 24, Issue 5, Pages 1406-1413
Publisher
Springer Nature
Online
2016-11-29
DOI
10.1245/s10434-016-5707-0
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Locally Advanced, Unresectable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline
- (2016) Edward P. Balaban et al. JOURNAL OF CLINICAL ONCOLOGY
- FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis
- (2016) Mustafa Suker et al. LANCET ONCOLOGY
- Radiological and Surgical Implications of Neoadjuvant Treatment With FOLFIRINOX for Locally Advanced and Borderline Resectable Pancreatic Cancer
- (2015) Cristina R. Ferrone et al. ANNALS OF SURGERY
- The Role of Stereotactic Body Radiation Therapy for Pancreatic Cancer: A Single-Institution Experience
- (2015) Shalini Moningi et al. ANNALS OF SURGICAL ONCOLOGY
- FOLFIRINOX Induction Therapy for Stage 3 Pancreatic Adenocarcinoma
- (2015) Eran Sadot et al. ANNALS OF SURGICAL ONCOLOGY
- Approach to Patients With Pancreatic Cancer Without Detectable Metastases
- (2015) Gregory M. Heestand et al. JOURNAL OF CLINICAL ONCOLOGY
- Pre-treatment carbohydrate antigen 19-9 does not predict the response to neoadjuvant therapy in patients with localized pancreatic cancer
- (2015) Mohammed Aldakkak et al. HPB
- Serum CA 19-9 Response to Neoadjuvant Therapy is Associated with Outcome in Pancreatic Adenocarcinoma
- (2014) Brian A. Boone et al. ANNALS OF SURGICAL ONCOLOGY
- Neoadjuvant Modified (m) FOLFIRINOX for Locally Advanced Unresectable (LAPC) and Borderline Resectable (BRPC) Adenocarcinoma of the Pancreas
- (2014) Marlo Blazer et al. ANNALS OF SURGICAL ONCOLOGY
- FOLFIRINOX for Locally Advanced Pancreatic Adenocarcinoma: Results of an AGEO Multicenter Prospective Observational Cohort
- (2014) L. Marthey et al. ANNALS OF SURGICAL ONCOLOGY
- FOLFIRINOX for Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma: The Royal Marsden Experience
- (2014) Sing Yu Moorcraft et al. Clinical Colorectal Cancer
- Outcomes with FOLFIRINOX for borderline resectable and locally unresectable pancreatic cancer
- (2013) Brian A. Boone et al. JOURNAL OF SURGICAL ONCOLOGY
- Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trial
- (2013) Somnath Mukherjee et al. LANCET ONCOLOGY
- Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
- (2013) Daniel D. Von Hoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- FOLFIRINOX in Locally Advanced Pancreatic Cancer: The Massachusetts General Hospital Cancer Center Experience
- (2013) J. E. Faris et al. ONCOLOGIST
- Modified FOLFIRINOX Regimen With Improved Safety and Maintained Efficacy in Pancreatic Adenocarcinoma
- (2013) Hemchandra Mahaseth et al. PANCREAS
- A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinoma
- (2012) Peter J Hosein et al. BMC CANCER
- Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators
- (2012) Matthew H. G. Katz et al. CANCER
- FOLFIRINOX for locally advanced and metastatic pancreatic cancer: single institution retrospective review of efficacy and toxicity
- (2012) Krishna S. Gunturu et al. MEDICAL ONCOLOGY
- Gemcitabine Alone Versus Gemcitabine Plus Radiotherapy in Patients With Locally Advanced Pancreatic Cancer: An Eastern Cooperative Oncology Group Trial
- (2011) Patrick J. Loehrer et al. JOURNAL OF CLINICAL ONCOLOGY
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
- (2011) Thierry Conroy et al. NEW ENGLAND JOURNAL OF MEDICINE
- Serum CA 19-9 as a Marker of Resectability and Survival in Patients with Potentially Resectable Pancreatic Cancer Treated with Neoadjuvant Chemoradiation
- (2010) Matthew H. G. Katz et al. ANNALS OF SURGICAL ONCOLOGY
- Pretreatment Assessment of Resectable and Borderline Resectable Pancreatic Cancer: Expert Consensus Statement
- (2009) Mark P. Callery et al. ANNALS OF SURGICAL ONCOLOGY
- Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000-01 FFCD/SFRO study
- (2008) B. Chauffert et al. ANNALS OF ONCOLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started